Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2022 07:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update

– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 ...
November 14, 2022 07:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer

– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting – Treatment was well tolerated, with promising clinical activity of pathologic complete...
November 02, 2022 07:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease

Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity currently being evaluated for the treatment of globally important cancers, viral diseases and disorders of the immune...
October 13, 2022 04:47 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech宣布获FDA授予IND申请批准，以评估安普利近®用于治疗新冠病毒感染后遗症的2期临床研究

佛罗里达州奥卡拉, Oct. 13, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（纽约证券交易所股票代码：American...
October 12, 2022 16:32 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

OCALA, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
October 12, 2022 08:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

OCALA, Fla, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
September 21, 2022 08:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Present at the Virtual Investor Long COVID Event

OCALA, Fla., Sept. 21, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
September 07, 2022 07:25 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference

OCALA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
September 06, 2022 07:30 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

OCALA, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
August 30, 2022 07:30 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma

Phase 2 to evaluate polarized dendritic cell vaccine, interferon alpha-2b, Ampligen and celecoxib for the treatment of HLA-A2+ refractory melanoma First patient dosing is expected in Q4, 2022 OCALA,...